MX2011008731A - Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. - Google Patents

Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.

Info

Publication number
MX2011008731A
MX2011008731A MX2011008731A MX2011008731A MX2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A
Authority
MX
Mexico
Prior art keywords
rtki
eye
delivery
compounds
pharmaceutical composition
Prior art date
Application number
MX2011008731A
Other languages
English (en)
Spanish (es)
Inventor
Bhagwati P Kabra
Malay Ghosh
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2011008731A publication Critical patent/MX2011008731A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011008731A 2009-03-03 2010-03-03 Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. MX2011008731A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15692209P 2009-03-03 2009-03-03
PCT/US2010/026033 WO2010101992A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (1)

Publication Number Publication Date
MX2011008731A true MX2011008731A (es) 2011-09-29

Family

ID=42678800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008731A MX2011008731A (es) 2009-03-03 2010-03-03 Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.

Country Status (12)

Country Link
US (2) US20100227905A1 (cg-RX-API-DMAC7.html)
EP (1) EP2403335B1 (cg-RX-API-DMAC7.html)
JP (1) JP5583146B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160135372A (cg-RX-API-DMAC7.html)
CN (1) CN102340991B (cg-RX-API-DMAC7.html)
AU (1) AU2010221369B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1012302A2 (cg-RX-API-DMAC7.html)
CA (1) CA2753690A1 (cg-RX-API-DMAC7.html)
ES (1) ES2508290T3 (cg-RX-API-DMAC7.html)
MX (1) MX2011008731A (cg-RX-API-DMAC7.html)
WO (1) WO2010101992A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105505B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MX2011007420A (es) 2009-07-06 2011-12-14 Akebia Therapeutics Inc Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
AU2011282252B2 (en) * 2010-07-21 2014-08-21 Alcon Research, Ltd. Pharmaceutical composition with enhanced solubility characteristics
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US20140160236A1 (en) * 2011-07-29 2014-06-12 The Regents Of The University Of California Lensfree holographic microscopy using wetting films
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
EP2825206A1 (en) 2012-03-16 2015-01-21 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US10159743B2 (en) 2012-03-16 2018-12-25 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1208162A1 (en) 2012-05-03 2016-02-26 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP3808339B1 (en) 2012-05-03 2025-11-12 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MX368142B (es) * 2013-04-30 2019-09-20 Intas Pharmaceuticals Ltd Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
RU2729731C2 (ru) 2014-12-15 2020-08-11 Зе Джонс Хопкинс Юниверсити Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
KR20240126072A (ko) 2015-01-27 2024-08-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
EP4414032A3 (en) 2015-09-23 2024-11-06 EyePoint Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of tie-2
EP3373978A4 (en) 2015-11-12 2019-06-26 Graybug Vision, Inc. AGGREGATION OF MICROPARTICLES FOR THERAPY
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
WO2018209155A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint, Inc. Tie-2 activators targeting the schlemm's canal
EP4065131B1 (en) * 2019-11-28 2024-09-18 Caprika Srl Rectal-use composition for the treatment of constipation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
HU220864B1 (en) * 1993-04-16 2002-06-29 Wakamoto Pharma Co Ltd Reversible, thermally gelling water-base medicinal compositions
CN1126545C (zh) * 1996-05-07 2003-11-05 东丽株式会社 眼科用制剂
SI1638941T1 (sl) * 2003-05-22 2010-11-30 Abbott Lab Inhibitorji indazol benzizoksazol in benzizotiazol kinaze
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN101006988A (zh) * 2005-09-26 2007-08-01 刘凤鸣 葛根素的缓释制剂
EP1965762A1 (en) * 2005-12-23 2008-09-10 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
BRPI0721885A2 (pt) * 2007-07-20 2014-02-25 Alcon Inc Formulação farmacêutica para distribuição de compostos inibidores de receptores de tirosina quinase (rtki) para os olhos

Also Published As

Publication number Publication date
EP2403335B1 (en) 2014-08-20
US20100227905A1 (en) 2010-09-09
CA2753690A1 (en) 2010-09-10
ES2508290T3 (es) 2014-10-16
WO2010101992A1 (en) 2010-09-10
JP5583146B2 (ja) 2014-09-03
JP2012519694A (ja) 2012-08-30
KR20160135372A (ko) 2016-11-25
EP2403335A1 (en) 2012-01-11
US20130137741A1 (en) 2013-05-30
AU2010221369B2 (en) 2014-03-13
CN102340991A (zh) 2012-02-01
EP2403335A4 (en) 2012-08-29
BRPI1012302A2 (pt) 2015-09-22
ZA201105505B (en) 2013-10-30
AU2010221369A1 (en) 2011-08-25
CN102340991B (zh) 2014-02-26
KR20110130454A (ko) 2011-12-05

Similar Documents

Publication Publication Date Title
MX2011008731A (es) Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
TW200733958A (en) Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
MX2021012934A (es) Lipidos de amina ionizables y nanoparticulas lipidicas.
PH12021551279A1 (en) Modified amine lipids
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
MX2011008680A (es) Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
MX349585B (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7.
MX2010010127A (es) 1,2,4-triazoles trisustituidos como moduladores de receptores de acetilcolina nicotinicos.
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
WO2009100441A3 (en) Depot formulations
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
JO3019B1 (ar) ثلاثي مستبدل 4،2،1-ثلاثي زولات
PL2081547T3 (pl) Postać galenowa do podawania składników czynnych poprzez śluzówkę
MX352434B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
WO2007048219A3 (en) Sustained drug release composition
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
WO2008140507A3 (en) Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
MX2010005013A (es) Composiciones intranasales.
WO2007076448A3 (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
MX382264B (es) Composiciones que comprenden amlodipina y bisoprolol.
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
MX2009012879A (es) Formulacion farmaceutica para suministrar a los ojos compuestos que inhiben el receptor tirosina cinasa (rtki).
TW200733959A (en) Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye

Legal Events

Date Code Title Description
FG Grant or registration